High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference25 articles.
1. High dose melphalan in the treatment of advanced neuroblastoma. Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group;Pritchard;Pediatr Blood Cancer,2005
2. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group;Matthay;N Engl J Med,1999
3. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial;Berthold;Lancet Oncol,2005
4. Cyclophosphamide/doxubicin vs cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Paediatric Oncology Group randomised phase 2 study;McWilliams;Med Pediatr Oncol,1995
5. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma;Kushner;J Clin Oncol,2004
Cited by 300 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. L-Glyceraldehyde inhibits neuroblastoma cell growth via a multi-modal mechanism on metabolism and signaling;2023-12-20
2. Prognostic factors for intermediate- or high-risk neuroblastomas in children in China;BMC Pediatrics;2023-12-06
3. Association of the minimal cyclophosphamide equivalent dose and outcome of microdissection testicular sperm extraction in patients with persistent azoospermia after chemotherapy;F&S Reports;2023-11
4. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes;Cancers;2023-10-03
5. Neuroblastoma chemoimmunotherapy: current results and application prospects;Russian Journal of Pediatric Hematology and Oncology;2023-07-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3